Innate Immunity in Sjögren's Syndrome

Overview

Journal Clin Immunol

Specialty Allergy & Immunology

Date 2017 Apr 12

PMID 28396235

Citations 44

Authors

Jeremy Kiripolsky

Liam G McCabe

Jill M Kramer

Affiliations

Soon will be listed here.

Abstract

Sjögren's syndrome (SS) is an autoimmune disease of exocrine tissue that primarily affects women. Although patients typically experience xerostomia and xerophthalmia, numerous systemic disease manifestations are seen. Innate immune hyperactivity is integral to many autoimmune diseases, including SS. Results from SS mouse models suggest that innate immune dysregulation drives disease and this is a seminal event in SS pathogenesis. Findings in SS patients corroborate those in mouse models, as innate immune cells and pathways are dysregulated both in exocrine tissue and in peripheral blood. We will review the role of the innate immune system in SS pathogenesis. We will discuss the etiology of SS with an emphasis on innate immune dysfunction. Moreover, we will review the innate cells that mediate inflammation in SS, the pathways implicated in disease, and the potential mechanisms governing their dysregulation. Finally, we will discuss emerging therapeutic approaches to target dysregulated innate immune signaling in SS.

Citing Articles

Vitamin D in Primary Sjogren's Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases.

Dabravolski S, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T, Sukhorukov V Diagnostics (Basel). 2024; 14(18).

PMID: 39335717 PMC: 11431467. DOI: 10.3390/diagnostics14182035.

G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.

Fang R, Zhou Z, Chu R, Guan Q, He F, Ge M Acta Pharmacol Sin. 2024; 45(12):2611-2624.

PMID: 39054339 PMC: 11579508. DOI: 10.1038/s41401-024-01350-4.

Male patients with primary Sjögren's syndrome have unique clinical manifestations and circulating lymphocyte profiles.

Liu H, Yuan J, Tan X, Song W, Wang S Clin Rheumatol. 2024; 43(6):1927-1937.

PMID: 38602613 DOI: 10.1007/s10067-024-06955-y.

Involvement of Epithelial-Mesenchymal Transition (EMT) in Autoimmune Diseases.

Sarrand J, Soyfoo M Int J Mol Sci. 2023; 24(19).

PMID: 37833928 PMC: 10572663. DOI: 10.3390/ijms241914481.

Metformin-induced activation of Ca signaling prevents immune infiltration/pathology in Sjogren's syndrome-prone mouse models.

Nascimento Da Conceicao V, Sun Y, Chai X, Ambrus J, Mishra B, Singh B J Transl Autoimmun. 2023; 7():100210.

PMID: 37711153 PMC: 10497794. DOI: 10.1016/j.jtauto.2023.100210.

References

Shiboski S, Shiboski C, Criswell L, Baer A, Challacombe S, Lanfranchi H . American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012; 64(4):475-87. PMC: 3349440. DOI: 10.1002/acr.21591. View

Ice J, Li H, Adrianto I, Lin P, Kelly J, Montgomery C . Genetics of Sjögren's syndrome in the genome-wide association era. J Autoimmun. 2012; 39(1-2):57-63. PMC: 3518871. DOI: 10.1016/j.jaut.2012.01.008. View

Piccinini A, Midwood K . DAMPening inflammation by modulating TLR signalling. Mediators Inflamm. 2010; 2010. PMC: 2913853. DOI: 10.1155/2010/672395. View

Cuello C, Palladinetti P, Tedla N, Di Girolamo N, Lloyd A, McCluskey P . Chemokine expression and leucocyte infiltration in Sjögren's syndrome. Br J Rheumatol. 1998; 37(7):779-83. DOI: 10.1093/rheumatology/37.7.779. View

Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S . FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling. Sci Transl Med. 2014; 6(232):232ra50. PMC: 4414050. DOI: 10.1126/scitranslmed.3008264. View

Wildenberg M, Welzen-Coppens J, van Helden-Meeuwsen C, Bootsma H, Vissink A, van Rooijen N . Increased frequency of CD16+ monocytes and the presence of activated dendritic cells in salivary glands in primary Sjögren syndrome. Ann Rheum Dis. 2008; 68(3):420-6. DOI: 10.1136/ard.2008.087874. View

Katsifis G, Moutsopoulos N, Wahl S . T lymphocytes in Sjögren's syndrome: contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol. 2007; 32(3):252-64. DOI: 10.1007/s12016-007-8011-8. View

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

Midwood K, Piccinini A, Sacre S . Targeting Toll-like receptors in autoimmunity. Curr Drug Targets. 2009; 10(11):1139-55. DOI: 10.2174/138945009789735101. View

10.

Yamada A, Arakaki R, Kudo Y, Ishimaru N . Targeting IL-1 in Sjögren's syndrome. Expert Opin Ther Targets. 2013; 17(4):393-401. DOI: 10.1517/14728222.2013.754427. View

11.

Maria N, Steenwijk E, IJpma A, van Helden-Meeuwsen C, Vogelsang P, Beumer W . Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome. Ann Rheum Dis. 2016; 76(4):721-730. DOI: 10.1136/annrheumdis-2016-209589. View

12.

Mavragani C . Mechanisms and New Strategies for Primary Sjögren's Syndrome. Annu Rev Med. 2017; 68:331-343. DOI: 10.1146/annurev-med-043015-123313. View

13.

Karlsen M, Hansen T, Nordal H, Brun J, Jonsson R, Appel S . Expression of Toll-like receptor -7 and -9 in B cell subsets from patients with primary Sjögren's syndrome. PLoS One. 2015; 10(3):e0120383. PMC: 4366264. DOI: 10.1371/journal.pone.0120383. View

14.

Norheim K, Harboe E, Goransson L, Omdal R . Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial. PLoS One. 2012; 7(1):e30123. PMC: 3254637. DOI: 10.1371/journal.pone.0030123. View

15.

Fagone P, Muthumani K, Mangano K, Magro G, Meroni P, Kim J . VGX-1027 modulates genes involved in lipopolysaccharide-induced Toll-like receptor 4 activation and in a murine model of systemic lupus erythematosus. Immunology. 2014; 142(4):594-602. PMC: 4107669. DOI: 10.1111/imm.12267. View

16.

Weng M, Wu D, Yang C, Peng H, Wang G, Wang T . Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer. Transl Res. 2016; 181:108-120. DOI: 10.1016/j.trsl.2016.10.001. View

17.

Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad K, Sutcliffe N . Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren's syndrome. Arthritis Rheumatol. 2014; 66(9):2545-57. DOI: 10.1002/art.38726. View

18.

Smedby K, Vajdic C, Falster M, Engels E, Martinez-Maza O, Turner J . Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008; 111(8):4029-38. PMC: 2288717. DOI: 10.1182/blood-2007-10-119974. View

19.

Kivity S, Arango M, Ehrenfeld M, Tehori O, Shoenfeld Y, Anaya J . Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review. J Autoimmun. 2014; 51:17-22. DOI: 10.1016/j.jaut.2014.02.008. View

20.

Teruel M, Alarcon-Riquelme M . Genetics of systemic lupus erythematosus and Sjögren's syndrome: an update. Curr Opin Rheumatol. 2016; 28(5):506-14. DOI: 10.1097/BOR.0000000000000310. View